Danna nan don nuna banners ɗin ku akan wannan shafin kuma ku biya kawai don nasara

Labaran Waya

Yin amfani da Cannabinoids don Magance Farfaɗowar Refractory, Dementia da Alzheimer's

Written by edita

MGC Pharmaceuticals Ltd. ya sanya hannu kan yarjejeniyar rarraba ta keɓance tare da Sciensus Rare, wani ɓangare na ƙungiyar kula da lafiya ta Burtaniya, Sciensus, don rarraba CannEpil® da CogniCann® a cikin manyan yankuna na Turai da Burtaniya.        

Yarjejeniyar ita ce don rarrabawa a cikin mahimman yankuna na Turai da Burtaniya don CannEpil®, da ake amfani da su don magance cututtukan ƙwayar cuta ta Drug Resistant Epilepsy, da CogniCann®, da ake amfani da su don kula da marasa lafiya da Dementia da cutar Alzheimer.

Sciensus Rare wani kamfani ne na samar da magunguna na kasa da kasa da ke kasar Netherlands, wanda ya kware wajen samar da magungunan cututtukan da ba kasafai ba ta hanyar gwajin gwaji na asibiti da shirye-shiryen samun damar likitanci da wuri, tare da gogewar sama da shekaru 30 wajen samar da ayyukan kula da lafiya, da fadada hanyoyin kiwon lafiya ga kayayyaki a ciki. Yammacin Turai.

A karkashin sharuɗɗan yarjejeniyar rarraba, Sciensus Rare an nada shi a matsayin keɓaɓɓen mai rarraba CannEpil® da CogniCann® a Denmark, Faransa, Italiya, Spain, Luxembourg, da Ingila, wasu manyan kasuwannin harhada magunguna a duniya, don farkon wa'adin shekaru 4. Bayan farkon watanni 12 na yarjejeniyar, Sciensus Rare za ta kasance ƙarƙashin ƙaƙƙarfan buƙatun odar siyayya don kula da keɓaɓɓen matsayin mai rarrabawa. Ƙungiyoyin sun amince cewa MGC Pharma za ta ci gaba da ɗaukar alhakin neman Izinin Kasuwa a waɗannan yankuna, yayin da Sciensus Rare za ta dauki nauyin aikace-aikace zuwa Shirye-shiryen Samun Farko da Shirye-shiryen Marasa Lafiya mai suna.

Roby Zomer, Manajan Darakta kuma Shugaba na MGC Pharma, yayi sharhi: "Sciensus Rare kyakkyawan kamfani ne na sabis na magunguna, tare da ƙwarewa da ƙwarewar da ake buƙata don haɓaka damar asibiti ga duka CannEpil® da CogniCann® ga waɗancan marasa lafiya waɗanda suka fi buƙata.

Wannan wani muhimmin mataki ne na fadada hanyoyin samun majinyata zuwa kayayyakinmu na harhada magunguna, da kuma sanya wani shiri na dogon lokaci don gina hanyoyin rarraba da ake bukata a yammacin Turai, daya daga cikin muhimman kasuwannin hada magunguna a duniya."

Gareth Williams, Shugaban Sciensus Rare, yayi sharhi: "Muna matukar farin cikin yin aiki tare da haɗin gwiwar MGC Pharmaceuticals a cikin kasuwar cannabis mai ban sha'awa ta duniya kuma muna fatan tallafawa likitocin da ke da damar yin amfani da CannEpil® da CogniCann®."

Game da marubucin

edita

Edita a shugaba na eTurboNew ita ce Linda Hohnholz. Ta dogara ne a HQ eTN a Honolulu, Hawaii.

Leave a Comment

Share zuwa...